Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dina Stroopinsky

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Leukemia & Lymphoma|June 28, 2016
MUC1 in hematological malignanciesDina Stroopinsky, Donald Kufe, David Avigan
Blood Reviews|August 20, 2013
Anti-CD20 monoclonal antibodies: beyond B-cellsIrit Avivi, Dina Stroopinsky, Tamar Katz
Transplant Immunology|December 1, 2012
A subset of CD8+ T cells acquiring selective suppressive properties may play a role in GvHD managementIrit Avivi, Dina Stroopinsky, Jacob M Rowe, et al.
Cancer Immunology, Immunotherapy : CII|January 18, 2012
Rituximab-induced direct inhibition of T-cell activationDina Stroopinsky, Tamar Katz, Jacob M Rowe, et al.
European Journal of Immunology|July 28, 2009
Allogeneic induced human FOXP3(+)IFN-gamma(+) T cells exhibit selective suppressive capacityDina Stroopinsky, Irit Avivi, Jacob M Rowe, et al.
Blood|November 28, 2013
MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cellsSuiyang Liu, Li Yin, Dina Stroopinsky, et al.
Oncotarget|June 4, 2016
MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemiaAshujit Tagde, Hasan Rajabi, Dina Stroopinsky, et al.
Haematologica|August 19, 2024
Cd39 and P2rx7-Wnt signaling enhance blast pathogenicity in an experimental model of acute myeloid leukemiaLili Feng, Haohai Zhang, Changchuin Mao, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 4, 2025
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin LymphomaSarit E Assouline, Amitkumar Mehta, Walter Hanel, et al.
Cancer Immunology, Immunotherapy : CII|July 14, 2022
Personalized tumor vaccine for pancreatic cancerShira Orr, Ling Huang, James Moser, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Leukemia & Lymphoma|June 28, 2016
MUC1 in hematological malignanciesDina Stroopinsky, Donald Kufe, David Avigan
Blood Reviews|August 20, 2013
Anti-CD20 monoclonal antibodies: beyond B-cellsIrit Avivi, Dina Stroopinsky, Tamar Katz
Transplant Immunology|December 1, 2012
A subset of CD8+ T cells acquiring selective suppressive properties may play a role in GvHD managementIrit Avivi, Dina Stroopinsky, Jacob M Rowe, et al.
Cancer Immunology, Immunotherapy : CII|January 18, 2012
Rituximab-induced direct inhibition of T-cell activationDina Stroopinsky, Tamar Katz, Jacob M Rowe, et al.
European Journal of Immunology|July 28, 2009
Allogeneic induced human FOXP3(+)IFN-gamma(+) T cells exhibit selective suppressive capacityDina Stroopinsky, Irit Avivi, Jacob M Rowe, et al.
Blood|November 28, 2013
MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cellsSuiyang Liu, Li Yin, Dina Stroopinsky, et al.
Oncotarget|June 4, 2016
MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemiaAshujit Tagde, Hasan Rajabi, Dina Stroopinsky, et al.
Haematologica|August 19, 2024
Cd39 and P2rx7-Wnt signaling enhance blast pathogenicity in an experimental model of acute myeloid leukemiaLili Feng, Haohai Zhang, Changchuin Mao, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 4, 2025
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin LymphomaSarit E Assouline, Amitkumar Mehta, Walter Hanel, et al.
Cancer Immunology, Immunotherapy : CII|July 14, 2022
Personalized tumor vaccine for pancreatic cancerShira Orr, Ling Huang, James Moser, et al.
Pageof 4